- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01183949
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, United States, MA02115
- Massachusetts General Hospital
-
Boston, Massachusetts, United States
- Dana Faber Cancer Institute
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan-Kettering Cancer Centre
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- MCW and Froedtert Clinical Cancer Center, Division of Neoplastic Diseases & Related Disorders
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability to understand the risks of the study and provide signed informed consent
- Age 18 years or older
- Relapsed and or Refractory MM
- Disease progression following at least two systemic treatments for MM
- Patient must be refractory to the last bortezomib
- ECOG performance status 0, 1 or 2
Exclusion Criteria:
- Pregnant or lactating females. Patients of childbearing potential must use appropriate birth control throughout the study
- Inadequate liver function
- Renal impairment
- Neutrophil count <1.0 x 10^9 /litre in the absence of growth factors
- Platelet count <50 x 10^9 /litre in patients in whom <50% of bone marrow nucleated cells are plasma cells and <30 x 10^9 /litre in patients in whom ≥50 % of bone marrow nucleated cells are plasma cells
- Hemoglobin <8g/dl in the absence of transfusion
- Treated corrected calcium >ULN
- Serum creatine phosphokinase >ULN
- All previous cytotoxic therapies for MM must have been completed at least four weeks prior to treatment with AT7519M (two weeks for all non-cytotoxic therapy)
- Patients may be receiving concomitant therapy with biphosphonates and low dose corticosteroids. Bisphosphonates doses should be stable for at least 30 days prior to study drug administration. Corticosteroids doses should be stable for at least 7 days prior to study treatment
- Prior peripheral stem cell transplant within 12 weeks
- Evidence of mucosal or internal bleeding and/or platelet transfusion refractory (unable to maintain a platelet count >50 x 10^9 /litre)
- Ongoing infection requiring treatment
- Previous radiotherapy within 2 weeks of the start of the study
- Having previously received treatment with a cyclin-dependent kinase or GSK3beta inhibitor
- Incomplete recovery from previous radiotherapy other than residual cutaneous effects or stable < Grade 2 gastrointestinal toxicity
- Prior radiotherapy to the head and neck region for head and neck tumors
- Previous malignancy, except for non-melanomatous skin carcinomas, in situ carcinomas or malignancies with low risk of recurrence.
- Any severe or uncontrolled systemic conditions (e.g. systemic infection) or current unstable or uncompensated respiratory or cardiac conditions which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol
- Incomplete recovery from surgery other than stable < Grade 2 toxicity
- Peripheral neuropathy > Grade 2
- Abnormal left ventricular ejection fraction (< lower limit of normal for the institution for a patient of that age) on echocardiogram
- History of an ischemic cardiac event, including myocardial infarction within 3 months of study entry
- Congestive cardiac failure of ≥ grade 3 severity according to NYHA functional classification
- Unstable cardiac disease
- History or presence of bradycardia (≤60bpm), left bundle branch block, heart block, cardiac pacemaker or significant atrial tachyarrhythmias
- If the patient will receive bortezomib (Velcade) during part C of the study, concurrent treatment with any medication known strongly to inhibit or induce CYP3A4, CYP1A2 and CYP2C19 which cannot be discontinued at least two week prior to treatment with AT7519M (other than corticosteroids)
- Concurrent treatment with any medication that prolongs QT interval and may induce Torsades de Pointes and which cannot be discontinued at least two weeks prior to treatment with AT7519M
- Family or personal history of long QTc syndrome or ventricular arrhythmias including ventricular bigeminy
- Previous history of drug-induced QTc prolongation
- Screening 12-lead ECG with measurable QTc interval according to Fridericia's Correction of >450 msecs
- Screening 12-lead ECG with ST depression >1 mm in 2 or more leads or T wave inversion in 2 or more contiguous leads
- Prior history of infection with human immunodeficiency virus (HIV), known active hepatitis B or C viruses
- Diffuse infiltrative pulmonary or pericardial disease
- Known hypersensitivity to bortezomib, boron or any of the excipients of VelcadeTM
- Epilepsy or other convulsive disorder requiring active management
- Serious psychiatric illness, active alcoholism or drug addiction that may hinder or confuse follow up evaluation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Patients will be enrolled into 3 groups which will run sequentially.
Groups A and B will receive AT7519M only, whereas Group C will receive AT7519M in combination with Bortezomib.
|
Part A: Nine patients will receive AT7519M as an intravenous infusion on days 1, 4, 8 and 11 of a three week cycle. The starting dose of AT7519M will be 21mg/m^2/dose and will be increased to 27mg/m^2/dose during subsequent cycles in the absence of AT7519M-related toxicities. Part B: Amendment clarified there will be no further exploration of AT7519M as a monotherapy. Part C: Amendment modified dose escalation to a conventional 3 + 3 design with a maximum total of 14 patients will be treated at the maximum tolerated dose.
Part C will treat between 3-26 patients with a combination of bortezomib and AT7519M in a dose escalation design.
The starting doses for the dose escalation are bortezomib 1 mg/m2 and AT7519M 14 mg/m2.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the clinical efficacy of AT7519M alone or in combination with bortezomib
Time Frame: Subjects with be followed until disease progression (an average of 4 cycles per subject. i.e an average of 84 days)
|
Efficacy will be assessed using the International Multiple Myeloma Working Group (IMWG) Response Criteria
|
Subjects with be followed until disease progression (an average of 4 cycles per subject. i.e an average of 84 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the type, incidence and severity of clinically significant treatment emergent adverse events as assessed by National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) V 4.03
Time Frame: Subjects with be followed until disease progression (an average of 4 cycles per subject, i.e an average of approximately 84 days)
|
Subjects with be followed until disease progression (an average of 4 cycles per subject, i.e an average of approximately 84 days)
|
|
To define the pharmacokinetic profile of AT7519M and bortezomib when administered alone or in combination with bortezomib
Time Frame: 2 cycles (i.e an average of 42 days)
|
The pharmacokinetic evaluation will include the calculation of plasma clearance and elimination phase half-life for AT7519M and bortezomib
|
2 cycles (i.e an average of 42 days)
|
To identify the maximum tolerated dose (MTD) of AT7519M in combination with bortezomib
Time Frame: Subjects with be followed until disease progression (an average of 4 cycles per subject, i.e an average of approximately 84 days)
|
The MTD will be based on the incidence of dose limiting toxicities
|
Subjects with be followed until disease progression (an average of 4 cycles per subject, i.e an average of approximately 84 days)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Antineoplastic Agents
- Bortezomib
Other Study ID Numbers
- AT7519M/0004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on AT7519M
-
NCIC Clinical Trials GroupAstex Pharmaceuticals, Inc.CompletedMantle Cell LymphomaCanada
-
NCIC Clinical Trials GroupAstex Pharmaceuticals, Inc.CompletedChronic Lymphocytic LeukemiaCanada
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Solid NeoplasmUnited States